Table 2.

Treatment-emergent adverse events occurring in > 1% of patients (safety analysis set)

Adverse event, n (%)	Placebo (n = 102)	ZYN002 (n = 109)
Patients with at least 1 TEAE	51 (50)	63 (57.8)
Upper respiratory tract infection	7 (6.9)	15 (13.8)
Nasopharyngitis	9 (8.8)	10 (9.2)
Vomiting	6 (5.9)	8 (7.3)
Pyrexia	7 (6.9)	5 (4.6)
Application site pain	1 (1.0)	7 (6.4)
Diarrhea	0 (0)	5 (4.6)
Gastroenteritis	1 (1.0)	7 (6.4)
Pharyngitis streptococcal	2 (2.0)	3 (2.8)
Rhinorrhea	2 (2.0)	2 (1.8)
Cough	0 (0)	3 (2.8)
Rash	1 (1.0)	2 (1.8)
Skin abrasion	1 (1.0)	2 (1.8)
Viral upper respiratory tract infection	2 (2.0)	1 (0.9)